Table 2

Research agenda

Eye involvementHead-to-head trial comparing interferon-alpha to TNFis
Controlled trials with IL-1 and IL-6 blockers
Controlled trials assessing the comparative efficacy and safety of different TNFis
Determining how long TNFis or interferon-alpha should be continued after remission is obtained
Defining remission regarding a decision to switch to a maintenance therapy or considering treatment discontinuation for eye involvement
Controlled trials determining whether glucocorticoids reduce the efficacy of interferon-alpha
Vascular involvementControlled trials to assess the efficacy and safety of anticoagulation for preventing relapses of venous thrombosis, post-thrombotic syndrome and recurrent arterial occlusive events
Observational studies to identify individual differences (saccular/diffuse fusiform/large vs small) that guide the choice of surgical intervention
Determining the optimal dose and duration of immunosuppressives after surgical intervention for peripheral artery aneurysms
Determining the optimal treatment of postoperative recurrent anastomotic aneurysms (extra-anastomosis bypass vs local aneurysm repair)
Determining the optimal management of intracardiac thrombosis
Nervous system involvementControlled studies for determining the optimal management of initial, refractory and recurrent parenchymal nervous system involvement and cerebral venous thrombosis
Determining the role of MRI and other laboratory tests in making treatment decisions and follow-up of patients with nervous system involvement
Gastrointestinal system involvementControlled studies for determining the optimal management of initial, refractory and recurrent gastrointestinal system involvement
Determining the role, optimal dose and duration of corticosteroids in acute relapses and whether they increase the risk of perforation
Determining whether a control colonoscopy is needed in patients with clinical remission and the optimal timing for control colonoscopy
OverallControlled trials to assess the benefit of concomitant immunosuppressive use with TNFis
Controlled trials assessing the efficacy of treatment modalities for patient important outcomes such as fatigue
  • IL, interleukin; TNFis, tumour necrosis factor alpha inhibitors.